These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 21355097)

  • 1. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
    Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
    J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
    Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
    Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
    Lyseng-Williamson KA; Yang LP
    Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
    Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
    Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
    Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
    Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
    Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.